Flavokawain B

Flavokawain B

SCHEMBL30384635

COc1cc(O)c(C(=O)C=Cc2ccccc2)c(OC)c1.[Na].[Na].[Na]

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.97
KMT2A Q03164 4/20 0.97
CYP3A4 P08684 3/20 0.97
TP53 P04637 2/20 0.97
ATM Q13315 1/20 0.97
HSD17B10 Q99714 1/20 0.97
MAOA P21397 2/20 0.82
MAOB P27338 2/20 0.82
CYP19A1 P11511 1/20 0.82
CYP2C9 P11712 1/20 0.82
CYP2C19 P33261 1/20 0.82
ABCG2 Q9UNQ0 7/20 0.81
MEN1 O00255 3/20 0.81
NPSR1 Q6W5P4 2/20 0.81
NFKB1 P19838 1/20 0.81
DPP4 P27487 1/20 0.81
NFKB2 Q00653 1/20 0.81
RELA Q04206 1/20 0.81
KCNA3 P22001 1/20 0.81
MKNK2 Q9HBH9 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Flavokawain B SCHEMBL25185055 0.99 MAPT (1.00) MAPTKMT2ACYP3A4TP53ATM
Flavokawain B SCHEMBL30382640 0.99 MAPT (1.00) MAPTKMT2ACYP3A4TP53ATM
Flavokawain B SCHEMBL29439356 0.99 MAPT (1.00) MAPTKMT2ACYP3A4TP53ATM
Flavokawain B SCHEMBL1675987 0.99 MAPT (1.00) MAPTKMT2ACYP3A4TP53ATM
Flavokawain B SCHEMBL1938260 0.99 MAPT (1.00) MAPTKMT2ACYP3A4TP53ATM
Flavokawain B SCHEMBL25193713 0.97 MAPT (0.97) MAPTKMT2ACYP3A4TP53ATM
Flavokawain B SCHEMBL25265211 0.97 MAPT (0.97) MAPTKMT2ACYP3A4TP53ATM
Flavokawain B SCHEMBL25278514 0.93 MAPT (0.88) MAPTKMT2ACYP3A4TP53ATM
Flavokawain B SCHEMBL25190550 0.92 MAPT (0.86) MAPTKMT2ACYP3A4TP53ATM
SCHEMBL25192230 0.91 MAPT (0.86) MAPTKMT2ACYP3A4TP53ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885KMT2A 3188/4885CYP3A4 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.